|
Aerocrine's novel asthma test in search of doctors, insurers
News & Observer With $22 million in cash, Aerocrine is positioned to finance operations through 2012, according to one analyst report, putting a premium on increased sales for its relatively unknown asthma test. The 15-year-old company, based on a scientific discovery … |
View full post on asthma – Google News